Evaluation of Neuropathological Effects of a High-Fat Diet in a Presymptomatic Alzheimer's Disease Stage in APP/PS1 Mice

• Published in: Journal of Alzheimer's disease Vol. 54; no. 1; p. 233
• Main Authors: Ettcheto, Miren, Petrov, Dmitry, Pedrós, Ignacio, Alva, Norma, Carbonell, Teresa, Beas-Zarate, Carlos, Pallas, Merce, Auladell, Carme, Folch, Jaume, Camins, Antoni
• Format: Journal Article
• Language: English
• Published: Netherlands 23.08.2016
• Subjects: Alzheimer Disease - metabolism; Alzheimer Disease - pathology; Amyloid beta-Peptides - metabolism; Amyloid beta-Protein Precursor - genetics; Amyloid beta-Protein Precursor - metabolism; Animals; Cholesterol - blood; Diet, High-Fat - adverse effects; Disease Models, Animal; Glucose - metabolism; Hippocampus - metabolism; Hippocampus - pathology; Humans; Insulin - blood; Male; Mice, Inbred C57BL; Mice, Transgenic; Neuroglia - metabolism; Neuroglia - pathology; Oxidative Stress - physiology; Peptide Fragments - metabolism; Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha - metabolism; Presenilin-1 - genetics; Presenilin-1 - metabolism; Prodromal Symptoms; Recognition (Psychology) - physiology; tau Proteins - metabolism; APPSwe/PS1dE9; tau; insulin receptor; Alzheimer’s disease; hippocampus; mitochondria
• ISSN: 1875-8908
• DOI: 10.3233/jad-160150

Alzheimer's disease (AD) is currently an incurable aging-related neurodegenerative disorder. Recent studies give support to the hypotheses that AD should be considered as a metabolic disease. The present study aimed to explore the relationship between hippocampal neuropathological amyloid-β (Aβ) plaque formation and obesity at an early presymptomatic disease stage (3 months of age). For this purpose, we used APPswe/PS1dE9 (APP/PS1) transgenic mice, fed with a high-fat diet (HFD) in order to investigate the potential molecular mechanisms involved in both disorders. The results showed that the hippocampus from APP/PS1 mice fed with a HFD had an early significant decrease in Aβ signaling pathway specifically in the insulin degrading enzyme protein levels, an enzyme involved in (Aβ) metabolism, and α-secretase. These changes were accompanied by a significant increase in the occurrence of plaques in the hippocampus of these mice. Furthermore, APP/PS1 mice showed a significant hippocampal decrease in PGC-1α levels, a cofactor involved in mitochondrial biogenesis. However, HFD does not provoke changes in neither insulin receptors gene expression nor enzymes involved in the signaling pathway. Moreover, there are no changes in any enzymes (kinases) involved in tau phosphorylation, such as CDK5, and neither in brain oxidative stress production. These results suggest that early changes in brains of APP/PS1 mice fed with a HFD are mediated by an increase in Aβ1 ‒ 42, which induces a decrease in PKA levels and alterations in the p-CREB/ NMDA2B /PGC1-α pathway, favoring early AD neuropathology in mice.